Compare INTT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | SKYE |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 44.9M |
| IPO Year | 1997 | 2013 |
| Metric | INTT | SKYE |
|---|---|---|
| Price | $15.08 | $0.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $13.50 | ★ $14.75 |
| AVG Volume (30 Days) | 145.8K | ★ 295.4K |
| Earning Date | 05-01-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $66,801,000.00 | N/A |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $6.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $5.24 | $0.63 |
| 52 Week High | $15.01 | $5.75 |
| Indicator | INTT | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 75.85 | 37.99 |
| Support Level | $7.21 | N/A |
| Resistance Level | N/A | $0.83 |
| Average True Range (ATR) | 0.92 | 0.05 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 93.27 | 5.77 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.